TriSalus Life Sciences (TLSI) Total Non-Current Liabilities (2020 - 2026)

TriSalus Life Sciences' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $55.4 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 3.54% year-over-year to $55.4 million in Q1 2026; TTM through Mar 2026 was $55.4 million, a 3.54% increase from a year earlier, with the FY2025 full-year figure at $59.0 million, up 42.12% from the prior year.
• Total Non-Current Liabilities eased to $55.4 million in Q1 2026 per TLSI's latest filing, from $59.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $59.0 million in Q4 2025 and bottomed at $10.8 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $38.2 million (2024), against an average of $35.0 million.
• Across the five-year window, Total Non-Current Liabilities jumped 227.97% in 2022 and declined 2.71% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $33.9 million in 2022, then decreased by 2.71% to $33.0 million in 2023, then grew by 25.79% to $41.5 million in 2024, then soared by 42.12% to $59.0 million in 2025, then decreased by 6.13% to $55.4 million in 2026.
• Per Business Quant, the three latest TLSI Total Non-Current Liabilities figures stand at $55.4 million (Q1 2026), $59.0 million (Q4 2025), and $58.2 million (Q3 2025).